Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)

Nancy H. L. Leung, Samuel M. S. Cheng, Carolyn A. Cohen, Mario Martín-Sánchez, Niki Y. M. Au, Leo L. H. Luk, Leo C. H. Tsang, Kelvin K. H. Kwan, Sara Chaothai, Lison W. C. Fung, Alan W. L. Cheung, Karl C. K. Chan, John K. C. Li, Yvonne Y. Ng, Prathanporn Kaewpreedee, Janice Z. Jia, Dennis K. M. Ip, Leo L. M. Poon, Gabriel M. Leung, J. S. Malik Peiris, Sophie A. Valkenburg, View ORCID ProfileBenjamin J. Cowling
doi: https://doi.org/10.1101/2022.08.25.22279158
Nancy H. L. Leung
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
2Laboratory of Data Discovery for Health; Hong Kong Science and Technology Park, New Territories, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bcowling@hku.hk leungnan@hku.hk
Samuel M. S. Cheng
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolyn A. Cohen
3HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario Martín-Sánchez
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Niki Y. M. Au
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leo L. H. Luk
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leo C. H. Tsang
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelvin K. H. Kwan
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Chaothai
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lison W. C. Fung
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan W. L. Cheung
3HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karl C. K. Chan
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John K. C. Li
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yvonne Y. Ng
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prathanporn Kaewpreedee
3HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janice Z. Jia
3HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennis K. M. Ip
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leo L. M. Poon
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
3HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
4Centre for Immunology and Infection; Hong Kong Science and Technology Park, New Territories, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriel M. Leung
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
2Laboratory of Data Discovery for Health; Hong Kong Science and Technology Park, New Territories, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. S. Malik Peiris
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
3HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
4Centre for Immunology and Infection; Hong Kong Science and Technology Park, New Territories, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophie A. Valkenburg
3HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
5Department of Microbiology and Immunology, Peter Doherty Institute of Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin J. Cowling
1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
2Laboratory of Data Discovery for Health; Hong Kong Science and Technology Park, New Territories, Hong Kong Special Administrative Region, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Benjamin J. Cowling
  • For correspondence: bcowling@hku.hk leungnan@hku.hk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background There are few trials comparing homologous and heterologous third doses of COVID-19 vaccination with inactivated vaccines and mRNA vaccines.

Methods We conducted an open-label randomized trial in adults >=18 years of age who received two doses of inactivated vaccine (CoronaVac) or mRNA vaccine (BNT162b2) >=6 months earlier, randomised in 1:1 ratio to receive a third dose of either vaccine. We compared the reactogenicity, immunogenicity and cell-mediated immune responses, and assessed vaccine efficacy against infections during follow-up.

Results We enrolled 219 adults who previously received two doses of CoronaVac and randomised to CoronaVac (“CC-C”, n=101) or BNT162b2 (“CC-B”, n=118) third dose; and 232 adults who previously received BNT162b2 and randomised to CoronaVac (“BB-C”, n=118) or BNT162b2 (“BB-B”, n=114). There were more frequent reports of mild reactions in recipients of third-dose BNT162b2, which generally subsided within 7 days. Third doses significantly increased neutralising PRNT50 antibody titers against ancestral virus and Omicron BA.1 variant in all four study arms, and against Omicron BA.2 in all arms except CC-C, with statistically significant improvements for recipients of a third dose of BNT162b2 over CoronaVac irrespective of prior vaccine type. Boosting of CD4+ T cells only occurred in CoronaVac-primed arms, but we did not identify overall differences between vaccine groups in CD4+ and CD8+ T cell responses. When Omicron BA.2 was circulating, we identified 58 infections with cumulative incidence of 15.3% and 15.4% in the CC-C and CC-B (p=0.93), and 16.7% and 14.0% in the BB-C and BB-B arms, respectively (p=0.56).

Conclusions Similar levels of incidence of infection in each arm suggest all third dose combinations may provide similar degrees of protection against prevalent Omicron BA.2 infection, despite very weak antibody responses to BA.2 in the recipients of a CoronaVac third dose. Further research is warranted to identify appropriate correlates of protection for inactivated COVID-19 vaccines.

Competing Interest Statement

BJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Roche and Sanofi Pasteur. BJC has received research funding from Fosun Pharma. The authors report no other potential conflicts of interest.

Clinical Trial

Clinicaltrials.gov NCT05057169

Funding Statement

This project was supported by the Health and Medical Research Fund (grant no. COVID19F09), and the Theme-based Research Scheme of the Research Grants Council of the Hong Kong Special Administrative Region, China (grant no. T11-705/21-N). BJC is supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract no. 75N93021C00015, and a RGC Senior Research Fellow Scheme grant (HKU SRFS2021-7S03) from the Research Grants Council of the Hong Kong Special Administrative Region, China. The funding bodies had no role in the design of the study, the collection, analysis, and interpretation of data, or writing of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol (Clinicaltrials.gov NCT05057169) was approved by the Institutional Review Board of the University of Hong Kong (ref: UW 21-492).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Clinicaltrials.gov registration: NCT05057169

Data Availability

Data to reproduce the results shown here will be posted on github after peer review and publication of our article.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted August 26, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)
Nancy H. L. Leung, Samuel M. S. Cheng, Carolyn A. Cohen, Mario Martín-Sánchez, Niki Y. M. Au, Leo L. H. Luk, Leo C. H. Tsang, Kelvin K. H. Kwan, Sara Chaothai, Lison W. C. Fung, Alan W. L. Cheung, Karl C. K. Chan, John K. C. Li, Yvonne Y. Ng, Prathanporn Kaewpreedee, Janice Z. Jia, Dennis K. M. Ip, Leo L. M. Poon, Gabriel M. Leung, J. S. Malik Peiris, Sophie A. Valkenburg, Benjamin J. Cowling
medRxiv 2022.08.25.22279158; doi: https://doi.org/10.1101/2022.08.25.22279158
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)
Nancy H. L. Leung, Samuel M. S. Cheng, Carolyn A. Cohen, Mario Martín-Sánchez, Niki Y. M. Au, Leo L. H. Luk, Leo C. H. Tsang, Kelvin K. H. Kwan, Sara Chaothai, Lison W. C. Fung, Alan W. L. Cheung, Karl C. K. Chan, John K. C. Li, Yvonne Y. Ng, Prathanporn Kaewpreedee, Janice Z. Jia, Dennis K. M. Ip, Leo L. M. Poon, Gabriel M. Leung, J. S. Malik Peiris, Sophie A. Valkenburg, Benjamin J. Cowling
medRxiv 2022.08.25.22279158; doi: https://doi.org/10.1101/2022.08.25.22279158

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1262)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (538)
  • Epidemiology (10055)
  • Forensic Medicine (5)
  • Gastroenterology (502)
  • Genetic and Genomic Medicine (2486)
  • Geriatric Medicine (240)
  • Health Economics (482)
  • Health Informatics (1653)
  • Health Policy (757)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (538)
  • Infectious Diseases (except HIV/AIDS) (11896)
  • Intensive Care and Critical Care Medicine (627)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2304)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1259)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2295)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (657)
  • Rheumatology (289)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (273)
  • Toxicology (44)
  • Transplantation (131)
  • Urology (100)